Treatment options for adenoid cystic carcinoma (ACC) of the salivary gland, a slowly growing tumor with propensity for neuroinvasion and late recurrence, are limited to surgery and radiotherapy. Based on expression analysis performed on clinical specimens of salivary cancers, we identified in ACC expression of the neurotrophin-3 receptor TrkC/NTRK3, neural crest marker SOX10, and other neurologic genes. Here, we characterize TrkC as a novel ACC marker, which was highly expressed in 17 out of 18 ACC primary-tumor specimens, but not in mucoepidermoid salivary carcinomas or head and neck squamous cell carcinoma. Expression of the TrkC ligand NT-3 and Tyr-phosphorylation of TrkC detected in our study suggested the existence of an autocrine signaling loop in ACC with potential therapeutic significance. NT-3 stimulation of U2OS cells with ectopic TrkC expression triggered TrkC phosphorylation and resulted in Ras, Erk 1/2 and Akt activation, as well as VEGFR1 phosphorylation. Without NT-3, TrkC remained unphosphorylated, stimulated accumulation of phospho-p53 and had opposite effects on p-Akt and p-Erk 1/2. NT-3 promoted motility, migration, invasion, soft-agar colony growth and cytoskeleton restructuring in TrkC-expressing U2OS cells. Immunohistochemical analysis demonstrated that TrkC-positive ACC specimens also show high expression of Bcl2, a Trk target regulated via Erk 1/2, in agreement with activation of the TrkC pathway in real tumors. In normal salivary gland tissue, both TrkC and Bcl2 were expressed in myoepithelial cells, suggesting a principal role for this cell lineage in the ACC origin and progression. Sub-micromolar concentrations of a novel potent Trk inhibitor AZD7451 completely blocked TrkC activation and associated tumorigenic behaviors. Pre-clinical studies on ACC tumors engrafted in mice showed efficacy and low toxicity of AZD7451, validating our in vitro data and stimulating more research into its clinical application. In summary, we describe in ACC a previously unrecognized pro-survival neurotrophin signaling pathway and link it with cancer progression.
INTRODUCTION
ACC is one of the most frequent (22%) types of salivary gland cancers, 1 and is amongst the most unpredictable and devastating tumors of the head and neck. ACC is characterized by insidious local spread and propensity to perineural invasion and distal metastases to lungs and bone. 2 Most ACCs are treated surgically with or without postoperative radiotherapy. Insufficient molecular insights into signaling that drives tumorigenesis and neural tropism in ACC combined with lack of reliable cell lines 3 are major impediments to the development of better treatment for this insidious cancer. With the goal to characterize signaling pathways involved in tumor growth and invasion to enhance therapeutic insight, we performed expression analysis of macro-dissected primary ACC specimens and characterized a novel ACC marker, TrkC/NTRK3, a receptor tyrosine kinase that binds neurotrophin 3. Our interest in TrkC was further stimulated by its overexpression in cancers (for example, neuroblastoma, 4 melanoma, 5 and breast cancer 6 ), trophic stimulation by NT-3 and by the availability of small-molecule Trk inhibitors. 7 Trk receptors and neurotrophins are involved in almost all stages of nervous system development [8] [9] [10] [11] where TrkC conveys NT-3-dependent pro-survival effects but triggers apoptosis in the absence of ligand. 12 Inactivating mutations in TrkC/NTRK3 have been recently associated with Hirschsprung disease, a developmental disorder characterized by the absence of ganglion cells in the myenteric and submucosal plexuses likely due to neural crest neuroblast migration defects. 13, 14 In cancers, where TrkC activities are not fully understood, TrkC prosurvival signaling was found to prevail over apoptotic signaling in the presence of NT-3, 15, 16 or when ligand requirement was bypassed by activating mutations 17 or fusions. 18 Potentially activating somatic mutations in the TrkC kinase domain have been reported in breast, lung, colon and pancreatic cancers. 17, [19] [20] [21] Rearrangements of NTRK3 and ETV6 genes (an ETV6-NTRK3 fusion) have been detected in congenital fibrosarcomas, secretory breast carcinomas and mammary analog of secretory carcinoma of salivary glands. [22] [23] [24] Overexpression of wild-type TrkC and/or other neurotrophin receptors (TrkA, TrkB and p75/NGFR) has been previously detected in cancers, including medulloblastoma, neuroblastoma and melanoma. Interestingly, the developmental cell of origin for all of these tumors is the neural crest.
Recent evidence suggests that TrkC/NT-3 signaling is linked with invasion in medulloblastoma, 26 ,27 melanoma 5 and breast cancer. 6, 28 In addition, TrkC expression has been correlated with the invasion into venous and nervous tissues in pancreatic ductal carcinoma; 29 however, the molecular and cellular mechanisms of such activity remain unclear. To explore the cellular and molecular consequences of TrkC signaling, TrkC was ectopically expressed in cancer cells lacking expression of any neurotrophin receptors or their ligands. Herein, we show that TrkC signaling is activated in human ACC and that activated TrkCs stimulated cell motility, chemotaxis, invasion and colony formation in soft agar, as well as induced fillopodia formation. We further show that NT-3-induced TrkC phosphorylation and pro-invasive cell behavior was effectively blocked by sub-micromolar concentrations of AZD7451, a small molecule pan-Trk inhibitor. 30 
RESULTS
ACC gene expression signature identifies expression of neurologic stem cell markers and elements of the Wnt and Notch pathways Gene expression profiles for human salivary ACC (n ¼ 7) was compared with profiles of salivary mucoepidermoid carcinoma (MEC, n ¼ 6), salivary adenocarcinoma (AD, n ¼ 2) and head and neck squamous cell carcinoma (HNSCC) (n ¼ 10) collected at the time of biopsy or resection at our institution (Table 1) . Expression array analyses identified genes whose expression discriminate ACC, MEC and HNSCC. Comparison of ACC versus MEC (P ¼ 0.01) revealed 3345 differentially expressed genes. Similar comparison between ACC and HNSCC identified 7127 differentially expressed genes, whereas MEC and HNSCC differed by 8137 genes (P ¼ 0.01).
Unsupervised clustering using 3345 ACC/MEC gene discriminators robustly classified these tumor types with all ACCs, excepting ACC-7, clustered together ( Figure 1a ) and revealed a set of 210 genes markedly overexpressed in ACC compared with MEC or HNSCC (Figure 1a and Supplementary Table 1) , which we referred to as TrkC-centered signature (TCCS). Two salivary adenocarcinomas (AD1, AD2) were included in the analyses and one (AD1) clustered with ACC and expressed TrkC whereas the other (AD2) clustered with MEC and expressed a low TrkC level. GO analyses of the TCCS that was highly expressed in ACC showed significant enrichment in genes associated with the Notch and Wnt pathways ( Table 2) that have previously been associated with neuron  differentiation and cancer.  31-33 Within TCCS, neural crest stem cell  markers SOX10,  34 MAP2,  35 SALL2  36 and SLITRK6,  37 as well as  melanoma markers SHC4  38 and MUM1  39 were also identified. Close co-expression of FGFR1 and EFNB3 with TrkC suggested possible co-function of these receptors in ACC.
TrkC is overexpressed and tyrosine-phosphorylated in ACC Enrichment of genes highly expressed in ACC and involved in neurologic development (TCCS) was surprising and highlighted by the relatively low expression of these genes in MEC and HNSCC. To validate TCCS findings, murine xenografts derived from primary ACC specimens (n ¼ 11) 40 were similarly analyzed, and expression array data combined with expression data from primary tumors (see above), re-normalized and re-clustered, as described above using 3345 differentially expressed genes. In this collective data set, 11 xenografted ACC specimens clustered with all but two primary ACC specimens (Figure 1b) . Consistent with clustering of primary ACC (Figure 1a) , genes highly expressed in ACC centered on TrkC and defined a gene cluster that was relatively overexpressed in ACC. TCCS components, such as EFNB3, GPM6B, SOX10 and TCF7L2 were again identified as highly expressed in ACC from this combined analyses. The TGF-b receptor TGFBR3 was also found adjacent to the NTRK3 cluster; however, its expression was not limited to ACC, but seen also in MEC, and to a lesser extent in HNSCC. Detection of TrkC expression suggested that other components of neurotrophic signaling may be expressed in ACC. Indeed, expression array data revealed that a portion of ACCs expressed neurotrophic receptors p75/NGFR or TrkB/NTRK2; however, TrkA/NTRK1 expression was not detected. Thus, TrkC appeared to be the only Trk receptor consistently and strongly expressed in ACC specimens, including xenografts (up to 430-100-fold higher levels compared with normal tissue control and in 17 of 18 specimens studied) (Figure 2a) . Interestingly, xenograft specimen ACCX5M1 (same as ACCX5, but a metastatic tumor obtained 2.5 years later 40 ) showed a much higher expression of TrkC as compared with original ACCX5, suggesting that TrkC expression may benefit metastasizing ACC cells. To confirm the expression array data and to determine the TrkC protein expression in ACC, immunoblotting was performed on clinical specimens. These studies revealed markedly increased TrkC expression in all ACCs examined, compared with normal salivary tissue, MECs or HNSCCs, where TrkC was barely detectable (Figure 2b and Supplementary Figure 1) . Expression of TrkC protein was also examined in xenografted ACC, confirming that its expression and phosphorylation is maintained in implanted tumors independent of passage number (Figures 2c, d) . Consistent with the microarray results, other neurotrophin receptors NGFR and TrkB were variably expressed in ACC (Figure 2b ).
ACC cells express full-length TrkC that undergoes phosphorylation and its ligand NT-3 Activating mutations and fusions of TrkC have been described in diverse tumor types. To determine if TrkC in ACC bears activating mutations, TrkC transcripts were amplified from primary ACC tumors and sequenced. TrkC ORFs isolated and sequenced from TrkC signaling in adenoid cystic carcinoma SV Ivanov et al all six TrkC-positive ACC tumors were full-length and wild-type. Remarkably, we found that all these specimens (ACC1-6) expressed the canonical isoform b that encodes a fully active protein (NM_002530), but also contained splicoform d (NM_001243101) that lacks exon 10 producing an 8-amino-acid (aa) in-frame deletion in the juxtamembrane TrkC domain. This isoform, which was expressed in ACC at levels similar to isoform b (data not shown), was previously described as a polymorphism, 41 but its biological significance remains unclear.
TrkC signaling varies depending on the availability of its ligand, NT-3. To determine if an autocrine loop between NT-3 and TrkC is active in ACC, as it was demonstrated recently for neuroblastoma, 16 primary tumors (n ¼ 7) and xenografted ACC specimens (n ¼ 11) were analyzed by RT-PCR for NT-3 expression. We detected and verified by sequencing NTF3 (NT-3) expression in both primary and xenografted ACC specimens, suggesting that an autocrine survival pathway may be active in ACC (Figure 2e ). Levels of NTF3 transcripts showed substantial variation from specimen to specimen with no obvious correlation with NTRK3 (R ¼ 0. results show that ACC tumors contain high levels of TrkC, and that TrkC signaling is persistently active in these tumors, likely owing to the autocrine NT-3 production.
Roles for TrkC and NT-3 in cell signaling, receptor internalization, and regulation of migration and invasion Although a link between TrkC/NT-3 expression and aggressive cancer behavior has been established, 6 ,42 the molecular and cellular consequences of TrkC overexpression in cancers are not well understood. Interestingly, TrkC expression in primary and xenografted tumor specimens did not correlate with other neurotrophin receptors, such as TrkA, TrkB or p75/NGFR, (Figures 2a and b) suggesting a special role for TrkC in this tumor type. To provide clues to potential consequences of TrkC signaling in ACC, we developed a cell line model that expressed no neurotrophin receptors except for TrkC. Owing to the lack of reliable ACC cell lines, 3 we resorted to forced expression of TrkC in human osteosarcoma cells U2OS, which lack endogenously expressed neurotrophic receptors and their ligands. Although this model may not necessarily replicate TrkC activities in ACC, our purpose here was to identify potential molecular mediators and behavioral consequences of TrkC signaling, as well as assess molecular efficacy of TrkC inhibition. In this cell model that easily tolerated high TrkC expression and allowed studying TrkC signaling with and without its ligand, addition of NT-3 triggered rapid and marked TrkC Tyr-phosphorylation, which could be completely blocked by a small-molecule pan-Trk inhibitor, AZD7451. (Figure 3b , compare panels 1 and 2). To validate these effects and to provide more details into the TrkC and p53 interaction, we performed immunoblot and immunoprecipitation experiments. These studies confirmed the stimulatory effects of NT-3 on Akt and Erk 1/2 activation in TrkC-expressing cells and showed that TrkC overexpression in U2OS cells in the absence of NT-3 increased total p53, and that TrkC can be detected in the p53-bound protein fraction (Figure 3c ). In agreement with our phospho-protein array data, NT-3 alleviated the TrkC-mediated upregulation of p53.
A similar phospho-RTK antibody array was employed to identify tyrosine phosphorylation in U2OS cells with and without TrkC expression or NT-3 stimulation. As expected, TrkA and TrkB phosphorylation was not detected in these cells, and TrkC tyrosine phosphorylation was confirmed upon NT-3 stimulation only in cells expressing TrkC (Figure 3b , panels 5-8). Remarkably, TrkC activation in the presence of NT-3 triggered VEGFR1 tyrosine phosphorylation, suggesting that NT-3 may promote angiogenesis in a TrkC-dependent manner.
Activation of Erk and Akt downstream of TrkC could involve Ras activation that was not tested in the antibody arrays. To determine if TrkC and NT-3 activated Ras, control-(vector) and TrkCexpressing U20S cells were stimulated with NT-3 for increasing time periods before measuring activated Ras. NT-3 stimulation resulted in rapid and sustained Ras activation, which was observed in TrkC-expressing cells only (Figure 3d ). These effects were consistent with previous reports demonstrating that Ras is a mediator of TrkC signaling, 6, 28 and further suggested that proliferative and survival axes are activated in the absence of additional neurotrophin components (for example, TrkA, TrkB, NGFR or their ligands).
As ligand-activated Trk signaling is associated with receptor internalization, 43 Ras activation is associated with cellular motility, migration, invasion, proliferation and survival. 44 To determine if TrkC expression or activation following NT-3 stimulation results in cellular migration, a scratch assay was performed on U2OS cells with and without TrkC expression. Addition of NT-3 did not alter migration of control cells but significantly (B1.8-fold) stimulated the migration of TrkC-expressing cells (Figure 4a , Po10 À 5 ). AZD7451 did not significantly alter migration of control U2OS cells (P ¼ 0.17) but inhibited the migration of TrkC-expressing cells (B2.3-fold, P ¼ 3.9 Â 10 À 8 ). To confirm the findings of the scratch assay suggesting that migration was increased by NT-3 stimulation of TrkC-expressing cells, a Boyden transmembrane migration assay was performed with and without NT-3 as attractant. Consistent with the scratch assay, NT-3 increased the migration of TrkC-expressing U2OS cells, but not control cells, and AZD7451 efficiently inhibited migration only in TrkC-expressing cells (Figure 4b ). The Boyden chamber assay was modified by adding matrigel coating to determine if NT-3 also altered invasive capacity. Control and TrkC-expressing U2OS cells have moderate invasive capacity under the conditions of our assay. Remarkably, NT-3 significantly promoted invasion of TrkC-expressing cells (B2.5-fold), but not control cells (Figure 4c) . AZD7451 blocked the increased invasion observed in the presence of NT-3.
Although U2OS cells are transformed, they inefficiently grow in soft agar, forming very few and relatively small colonies. Addition of NT-3 to TrkC-negative cells or expression of TrkC in the absence of NT-3 did not enhance the ability of U2OS cells to grow in soft CTBP1  CTBP1  ATXN3  MAP2  CTBP2  CTBP2  CRIM1  SALL2  CXXC4  KAT2A  EFNB3  SOX10  FBXW11  NOTCH1  GPM6B  SLITRK6  LRP6  GPSM1  SMAD4  NDRG2  TBL1X  NTRK3  TCF7L1  SEMA6D  TCF7L2  SMARCC2  WNT6 SMARCE1
TrkC signaling in adenoid cystic carcinoma SV Ivanov et al Effects of TrkC and NT-3 on cytoskeleton components Migration and invasion require coordinated restructuring of the cytoskeleton, and Ras activation is involved in this process. 45 The extent of cytoskeletal rearrangement resulting from TrkC activation was determined by F-actin staining with phalloidin-FITC. Upon NT-3 stimulation, TrkC-expressing cells showed apparent cytoskeleton rearrangement reflected in F-actin condensation (puncta) (Figure 5a , upper panel) and developed protrusions enriched with F-actin (Figure 5a , middle and bottom panels). These effects were similar to the NT-3-triggered changes in the morphology of neuroblastoma cells described earlier. 46 TUBB2B, a class II b-tubulin, is thought to be expressed exclusively in nervous tissue (http://biogps.org/) and critically involved in neuronal migration. 47 Expression array study revealed that this gene is expressed in the majority of ACC specimens (Figure 5b, bottom panel) . Immunofluorescent staining TrkC-or vector-expressing U2OS cells with TUBB2B antibodies revealed that TrkC, indeed, stimulates expression of TUBB2B in these cells, suggesting that TrkC may affect restructuring of the cytoskeleton (Figure 5b, upper panel) . Finally, we asked if identification of TrkC protein partners in tumor cells may help understanding molecular mechanisms involved in the TrkC-dependent motility and migration. To this end, we performed immuno-precipitation of TrkCbinding proteins from a whole-cell primary ACC lysate. Massspectrometry of protein bands separated by electrophoresis identified among other potential TrkC partners Myh9 that has been recently associated with cytoskeletal restructure during cancer cell invasion, 48 and components of newly identified WASH complex Swip, strumpellin, Fam21a, and Capza2 (Supplementary Figure 3) involved in trafficking and Arp2/3-mediated actin assembly. 49 Taken together, all these observations suggest an important role for the TrkC/NT-3 interaction in cytoskeleton regulation.
Upregulation of p-Erk1/2 and Bcl2 in TrkC-positive ACC cells Upregulation of Erk 1/2 by neurotrophins is linked with Bcl2 upregulation (http://www.genome.jp/kegg-bin/show_pathway? hsa04722). Also, overexpression of TrkC was associated with Erk1/2 and Bcl2 upregulation in a recent study on cylindromas. 50 As in our study NT-3 induced Erk1/2 phosphorylation in a TrkCdependent fashion (Figure 3c ), we stained clinical ACC specimens to define if activated Erk1/2 and Bcl2 are co-expressed with TrkC in ACC. Our analysis confirmed that, similar to cylindroma, ACC specimens coexpress TrkC, p-Erk1/2 and Bcl2 in their neoplastic myoepithelial layer ( Figure 6 ). No expression of these genes was detected in MEC in agreement with lack of TrkC expression in this cancer. Interestingly, normal salivary gland tissue showed TrkCand Bcl2-positive signals in myoepithelial cells (Supplementary Figure 4) . This finding, however, was not entirely unexpected given important roles that these cells have in ACC. 51 
AZD7451 suppresses ACC tumor growth in vivo
To assess AZD7451 effect on ACC growth, we took advantage of two xenograft models of human ACC: ACCX6, a model of metastatic ACC, and ACCX9, a primary tumor model. 40 Significant anti-tumor activity of single-agent AZD7451 following oral administration of a 50 mg/kg daily dose was seen in the ACCX6 model (tumor growth inhibition (TGI) ¼ 64%, Po0.05), while ACCX9 growth did not differ as much at the 35-day end point (TGI ¼ 43%, P40.05) (Figure 7a ). Analysis of BrdU incorporation performed on the same model, however, showed a robust reduction in the proliferation index calculated as percentage of BrdU-positive cells followed from 17 to 5%, TrkC signaling in adenoid cystic carcinoma SV Ivanov et al Po10 À 5 , suggesting that AZD7451 is efficacious. The observed discrepancy between the molecular and tumor growth data could be explained by the sluggish growth at days 1-21 and thus insufficient time to observe true difference in the tumor size. The growth suppressive effects of AZD7451 could not be explained by its toxicity as no significant change in body weight was observed (Supplementary Figure 5) . Based on these preclinical studies, we demonstrate significant data supporting single-agent Trk kinase inhibition as a potential therapeutic option in ACC that warrants further investigation.
DISCUSSION
In this study, we characterize a novel ACC marker, receptor tyrosine kinase TrkC/NTRK3. We detected unusually high TrkC expression levels in ACC (up to B100-fold as compared with the normal salivary tissue) raising an important question if this RTK may serve as a driver of ACC. Lack of activating mutations suggested that malignant ACC cells may benefit from increased activity of wild-type TrkC signaling and that this can be achieved via spontaneous TrkC dimerization and activation due to overexpression 52 or through interaction with its only known ligand NT-3. As other neurotrophin receptors did not appear to correlate with TrkC expression, we asked if TrkC signaling alone would be sufficient to stimulate pro-invasive signaling and cell behavior. As we report here, TrkC-expressing U2OS cells in response to NT-3 stimulated: (1) TrkC tyrosine phosphorylation, (2) Ras, Erk1/2, Akt and VEGFR1 activation, (3) cell motility, (4) chemotaxis toward NT-3, (5) adherence-independent growth and (6) outgrowth of F-actin-rich processes typical for migrating cells (Figures 4 and 5) . Without NT-3, TrkC remained unphosphorylated, did not stimulate any pro-tumorigenic qualities, and had anti-tumorigenic signaling effects, in agreement with the dependence receptor paradigm. 53 In agreement with previous studies, NT-3 appeared to be the only neurotrophin capable of activating TrkC, as NGF, BDNF and NT-4 failed to induce TrkC phosphorylation (data not shown). These observations suggest that highly overexpressed TrkC is oncogenic when NT-3 is available, stimulating further research into the autocrine TrkC/NT-3 signaling that we discovered in ACC.
Without NT-3, however, TrkC was reported to induce apoptosis and thus may suppress tumor progression. 15 Our studies revealed novel molecular mechanisms of this NT-3-independent mode of TrkC function. Thus, TrkC in the absence of ligand stimulated TUBB2 expression (Figure 5b ) and showed opposite effects on Akt and Erk 1/2 activation (Figure 3c ). We also demonstrated that TrkC alone may stimulate the expression of total and serine-phosphorylated p53, that this effect can be alleviated by NT-3, and that TrkC may physically interact with p53 (Figures 3b and c) . Interestingly, TrkA, which is also considered a dependence receptor with a pro-apoptotic function that is similar to TrkC when its ligand is not available, 12,53 binds p53, which mediates TrkA activities. [54] [55] [56] [57] Tumor-suppressive TrkC activities suggest that association of TrkC overexpression with good prognosis observed in medulloblastoma 4 may be explained by lack of NT-3 stimulation. Indeed, autocrine TrkC/NT-3 loops detected recently in neuroblastomas were linked with poor prognosis. 16 Upregulation of Bcl2 along with TrkC in ACC, which is also observed in CYLD-deficient tumors that overexpress TrkC, 50 is an intriguing discovery, given the important role that Bcl2 has in cell survival and, particularly, the resistance to radio-and chemotherapies. 58 High Bcl2 levels that we detected in ACC cells are supported by a study performed on four ACC specimens 59 and may explain the relative resistance of this cancer to cytotoxic therapies, making development of targeted approaches even more justified. Expression of TrkC in normal myoepithelial cells of salivary gland provides an interesting insight into the potential cell origin of ACC. ACC is thought to arise from the intercalated salivary duct where myoepithelial cells are abundant, 60, 61 and is histologically and clinically distinct from MEC, whose origin is linked with the excretory duct. 61, 62 Accordingly, our expression array data reliably discriminated between these two cancers and pointed at TrkC as one of the most distinguishing marker of ACC. As myoepithelial cells have important roles in normal salivary gland functions and the pathogenesis of adenoid cystic carcinoma, 63 ,64 characterization of TrkC as a previously unknown marker of these cells shed more light onto their function, origin and role in ACC.
Overall, our findings reveal previously unknown autocrine NT-3/ TrkC signaling pathway in ACC that may be potentially targeted with small-molecule inhibitors. A novel pan-Trk inhibitor AZD7451 was characterized in our study as a potent TrkC inhibitor, which blocks its tyrosine phosphorylation in a nanomolar range and suppresses TrkC/NT-3-mediated cell migration, motility, invasion and growth in soft agar (Figures 4a-c) . It is reasonable, therefore, to suggest that this drug may be used to block ACC neuroinvasion and growth, and our pre-clinical assessment of its activity on a murine xenograft that model invasive ACC supports its tumorsuppressive properties (ACCX6, Figure 7a ). In conclusion, distorted neurologic signaling detected in ACC advances our understanding of its molecular etiology, suggests similarity of its molecular pathology with neural crest cancers, and stimulates development of multi-drug treatment modalities that target TrkC/NT-3, Ras, Erk 1/2, Akt and Bcl2.
MATERIALS AND METHODS

Head and neck cancer patients and tumor specimens
The study includes three independent cohorts of head and neck cancer patients treated at Vanderbilt Ingram University Medical Center (VICC), the University of Virginia (UVA) Hospital, and MD Anderson Cancer Center. Primary salivary cancer and HNSCC specimens were obtained from 36 patients: adenoid cystic carcinoma (n ¼ 28), mucoepidermoid carcinoma (n ¼ 6), adenocarcinoma (n ¼ 2), HNSCC (n ¼ 10). Patients who were treated between 2003 and 2008 provided written consent to have tissue collected for research purposes from the Institutional Review Board (IRB#030062, WGY). The UVA ACC specimens used in the study (n ¼ 11) were grown as murine xenografts, as previously described. 40 
RNA isolation and expression array analyses
Total RNA was isolated from snap-frozen clinical macro-dissected specimens, as described before 65 or from cell lines using miRNeasy or RNeasy kits (Qiagen, Valencia, CA, USA). RNA quality and quantity were determined using Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) and Nanodrop ND-1000 (NanoDrop Products, Wilmington, DE, USA). Complementary RNA was prepared from 100 ng of total RNA following the Affymetrix 3 0 IVT Express kit labeling protocol and standardized array processing procedures recommended by Affymetrix, including hybridization, fluidics processing and scanning of the Affymetrix HG-U133 Plus 2.0 arrays. The raw data (Affymetrix CEL files) were normalized using RMA (Robust Multi-array Analysis). Gene Ontology analyses of differentially expressed genes was performed using WebGestalt, 66 GSEA, 67 and g:Profiler 68 portals.
RT-PCR and sequencing
To produce NTRK3 cDNA for sequencing from clinical RNA specimens, the following primers were designed and used: NTRK3F1 ( 
Cell lines and transgenic expression
The osteosarcoma cell line U2OS was transfected with NTRK3 expression construct (Myc-DDK-tagged ORF clone, NM_002530) purchased from OriGene (Rockville, MD, USA) and validated by sequencing. U2OS clones with constitutive expression of TrkC were produced via G418 selection.
Antibodies for western analysis, TrkC phosphorylation assay, and immunohistochemical staining TrkC/NTRK3, TrkB/NTRK2, p75/NGFR, TGFBR3, phospho-Akt(Ser473) and phospho-Erk1/2 rabbit monoclonal antibodies were from Cell Signaling (Danvers, MA, USA). Phospho-Tyr antibodies were from BD Transduction Laboratories (San Jose, CA, USA). Polyclonal Ephrin B3 antibody was from Novus Biologicals (Littleton, CO, USA), and DO1 p53 antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). For IHC, Cell Signaling TrkC antibody (1:100 dilution), NT-3 antibody from Santa Cruz Biotechnology (N-20, 1:300), and Bcl2 antibody from Leica Microsystems (PA0117, Buffalo Grove, IL, USA) were used with Novocasra Bond Polymer Refine Detection system, as recommended by the manufacturer.
Ras activation and protein phosphorylation assays
To measure Ras activity, Ras Activation Assay kit produced by Cytoskeleton (Denver, CO, USA) was used. Protein phosphorylation was detected using the Human Phospho-Kinase and Phospho-RTK Antibody Arrays (R&D, Minneapolis, MN, USA).
AZD7451
AZD7451 is a potent small-molecule inhibitor of Trk kinases with a high degree of specificity and selectivity demonstrated as compared with other kinases. 30 AZD7451 was found to inhibit the in vitro activity of all three Trk Cell motility, migration, invasion and colony formation in soft agar Scratch (wound healing) assay was performed as described, 69 following the inhibition of proliferation using mitomycin C at 5 mg/ml. Migration and invasion assays used 8.0 mm polycarbonate membrane inserts for 24-well plates (BD Biosciences, Franklin Lakes, NJ, USA). Briefly, 2 Â 10 4 of serumstarved cells were loaded into each insert in serum-free DMEM media and incubated in a CO 2 incubator for 22 h with or without NT-3 (PeproTech, Rocky Hill, NJ, USA) added at 100 ng/ml to bottom media supplemented with serum. Colony formation was determined with or without NT-3 (100 ng/ml) in 0.3% agar/complete DMEM. In all these experiments, Trk inhibitor AZ7451 was used at 100 nM.
Immunoprecipitation and mass spectrometry
Proteins that bind TrkC were determined following immunoprecipitation with Cell Signaling TrkC antibodies and Dynabeads (Carlsbad, CA, USA). Protein bands were separated using PAAG and bands isolated after staining with coomassie blue. Protein identification was determined via Mass Spectrometry by ProtTech (Norristown, PA, USA).
Cytoskeleton visualization
Mouse monoclonal anti-TUBB2B (Abnova, Walnut, CA, USA) with antimouse Alexa 555 (Invitrogen, Carlsbad, CA, USA) and FITC-phalloidin (Sigma, St Louis, MO, USA) were used to stain cells according to manufacturer's instructions. Nuclei were counterstained with DAPI.
AZD7451 studies on ACC xenografts
The in vivo efficacy on AZD7451 was evaluated in a series of primary ACC tumor xenograft models 40 through the South Texas Accelerated Research Therapeutics (San Antonio, TX, USA) program. Animals were maintained in accordance with the Institutional Animal Care and Use Committee guidelines. Female at hymic nu/nu mice (Harlan Sprague-Dawley) between 4-6 weeks of age were housed on irradiated corncob bedding (Teklad bedding) in individually ventilated cages (Sealsafe Plus, Tecniplast, Exton, PA, USA) on a 12-h light-dark cycle at 70-74 1F (21-23 1C) and 40-60% humidity. Mice were fed water ad libitum (reverse osmosis, 2 ppm Cl 2 ) and an irradiated standard rodent diet (Teklad 2919) consisting of 18% protein, 5% fat and 4% fiber. Fragments of human ACC tumor specimens, ACCX6 and ACCX9 were subcutaneously implanted and grown to produce cohorts averaging n ¼ 8 per group. Tumor-bearing mice were randomized into control and treatment groups when tumors reached B0.2 cm 3 in size. AZD7451 treatment was given by oral administration at 50 mg/kg, following a daily schedule for 35 days total dosing alongside vehicle (0.5 HPMC/0.1% Tween 80) controls. To assess AZD7451 toxicity, animals were observed daily and weighed twice weekly using a digital scale; data including individual and mean gram weights (mean We ± s.d.), mean percent weight change versus Day 0 (%vD 0 ) and mean percent weight change versus prior measurement (%vD À x ) were recorded for each group and plotted at study completion. To assess AZD7451 efficacy, tumor dimensions were measured twice weekly by a digital caliper and data including individual and mean estimated tumor volumes (Mean TV±s.e.m.) recorded for each group; tumor volume was calculated using the formula TV ¼ width 2 Â length Â 0.52. At the end point, percent (%TGI) values were calculated and reported for each treatment group (T) versus control (C) using initial (i) and final (f) tumor measurements by the formula: %TGI ¼ 1 À T f À T i /C f À C; single agent or combination therapies resulting in a TGI 458% at study completion are considered active in the tested model at the evaluated treatment regimen according to NCI guidelines. Statistical differences in tumor volume were determined using a one-tailed t-test. BrdU incorporation studies were performed upon intraperitoneal injection with 1 mg of BrdU (BD Biosciences, San Jose, CA, USA) in 200 mkl PBS 2 h before killing the mice. Tumor cells positively stained with BrdU-antibody (Cell Signaling) were counted from 10 high-power fields ( Â 40) (4300 cells per field) and proliferative index determined as BrdU-positive cells divided by total cell count.
